Applying synthetic lethality for the selective targeting of cancer.
about
The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancerDrugging the addict: non-oncogene addiction as a target for cancer therapyMolecular Aspects of Head and Neck Cancer TherapyPrediction of Genetic Interactions Using Machine Learning and Network PropertiesEpigenetic reduction of DNA repair in progression to gastrointestinal cancerSelective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing DrugsDNA-damaging autoantibodies and cancer: the lupus butterfly theory.Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance.Defective sister chromatid cohesion is synthetically lethal with impaired APC/C function.Mechanisms of a novel anticancer therapeutic strategy involving atmospheric pressure plasma-mediated apoptosis and DNA strand break formation.Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.Massively parallel high-order combinatorial genetics in human cellsAdvances in small-molecule drug discovery for triple-negative breast cancer.A synthetic lethal approach for compound and target identification in Staphylococcus aureusCancer in the parasitic protozoans Trypanosoma brucei and Toxoplasma gondii.Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery.Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer.High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinomaUSP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer.Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression.The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations.Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes.Targeting MYC in cancer therapy: RNA processing offers new opportunities.Triple-negative breast cancer: treatment challenges and solutions.SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells.Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancerMicroRNA-based screens for synthetic lethal interactions with c-MycPreclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancerTP53 mutations, expression and interaction networks in human cancersInvestigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.Targeting tumor suppressor genes for cancer therapy.The 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic Lethality.Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.Combine and conquer: challenges for targeted therapy combinations in early phase trials.PARP inhibitors as antitumor agents: a patent update (2013-2015).Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets.Defeat mutant KRAS with synthetic lethality.Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC.Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance.
P2860
Q26766285-312EDC7C-ADF3-4713-9C85-BC9984977FBBQ28079559-AFE87869-7A38-4F5F-89FF-0B607BBE495CQ28082815-899FB075-5491-4E0A-8D50-52F830A85865Q28084302-172504C7-BAF2-4C41-8B34-95F70A6A3F31Q28262162-E34EA4E8-1693-401C-87C4-04B315D36D10Q28547522-38BD40A6-AC1F-4FFA-9C3C-CBA8B03AFC3DQ30251723-9EB1F928-1426-4C58-B057-525A1691E395Q30665308-38A5E5DC-56C5-43C8-8CC7-ED4EEEEA964FQ30667509-A6AC4F6F-07E1-4B53-8051-FF48EA49C386Q33465772-D95A99BE-B801-4ECD-B0D3-19A25B9E6B34Q34514973-E18D0771-0D57-4417-B664-3F1543CC8EFAQ35747682-87CDBAB5-6B8A-4304-844D-4A898DA0F28EQ35818491-87E7322A-0763-4B73-8554-C24F1BE7EF18Q35855932-F96111E0-44A5-4C7D-AE95-44498BF0AB7FQ35895770-9AEB0B20-DAD8-41FF-B791-0B1EAC534944Q36024654-CEDC9A8B-E640-45F1-B1E5-27877BB39259Q36111892-4B8DB57C-853A-47F6-B9E3-AC078F565A79Q36231927-ED3BE764-2D95-4D30-8C59-0422A6711AEBQ36268425-C858BD5F-5CBE-4EDF-BC60-F2619BDCD6B0Q36545721-2DCA8BF2-E9CB-425E-BABA-B3D33C909053Q36623671-78A91106-2130-4537-A025-C6FBC251D0C6Q36653537-32926FA7-3D29-4AFE-900F-AD83886945EAQ36762189-26AC9122-DF0B-433F-A6F7-DC8630535D57Q36940085-93EEC4D3-0481-49A5-95DD-4EEBC3BB171BQ37188977-197D004F-7A4C-4D2A-BF4D-6FF48C8752DDQ37247500-4A9DD305-73D5-40A4-9572-91F0324EFD16Q37495218-F4C2DB9B-1DA0-4006-BFE0-4F48D499B1CCQ37701538-9684B575-57AC-474D-AAC9-BDBA8D424E66Q37702327-B047E37A-4EF7-44D3-B348-BF18D0ABEA48Q38323440-FC1D6166-6CFF-4D97-A4F0-D2C03EB5A7A5Q38601568-617810CC-588E-4795-8CDF-1F37E77DD2FDQ38652190-A6038C4C-8A0E-4EB5-A27C-6A6A94FD30B2Q38656763-0D7CB60C-F4A6-4DE3-B638-015BBC2D87F8Q38734451-B7109C89-4963-4B74-B5BB-8E5ACAC4C177Q38795712-076566B3-0F0A-40DB-BD1D-488FEADABE28Q38817669-0CC09C5F-186A-4ED6-9819-6B20CC912D1BQ38823713-3C9413AA-B214-491A-B6F4-3B72000ACA09Q38837319-E7715562-579C-4790-8179-987C2C42FF5FQ38840383-48ADA313-3E7B-4570-AD1B-F2F68B439990Q38868212-E8F90688-A19A-495F-B9BA-9B715C183D19
P2860
Applying synthetic lethality for the selective targeting of cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Applying synthetic lethality for the selective targeting of cancer.
@en
type
label
Applying synthetic lethality for the selective targeting of cancer.
@en
prefLabel
Applying synthetic lethality for the selective targeting of cancer.
@en
P356
P1476
Applying synthetic lethality for the selective targeting of cancer
@en
P2093
Donal P McLornan
Ghulam J Mufti
P304
P356
10.1056/NEJMRA1407390
P407
P50
P577
2014-10-01T00:00:00Z